Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Gisslinger, H; Ludwig, H; Linkesch, W; Chott, A; Fritz, E; Radaszkiewicz, T.
Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
Lancet. 1989; 1(8639):634-637
Doi: 10.1016/S0140-6736(89)92142-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- 31 patients with thrombocytosis associated with myeloproliferative disorders were included in a prospective trial of long-term interferon therapy. 6 patients (19%) had side-effects which required withdrawal of interferon within one year. 22 patients (71%) achieved and maintained a complete response (platelet count less than 440 x 10(9)/l) for at least twelve months, with reduction or abolition of symptoms associated with thrombocytosis and a significant fall in bone-marrow megakaryocytes. At twelve months, 25 patients were randomly allocated to maintenance or withdrawal of interferon. Thrombocytosis recurred rapidly when treatment was stopped, but a second remission could be achieved by resumption of interferon therapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Bone Marrow Examination -
- Clinical Trials -
- Female -
- Humans -
- Interferon Type I - adverse effects
- Male - adverse effects
- Megakaryocytes - adverse effects
- Middle Aged - adverse effects
- Myeloproliferative Disorders - blood
- Platelet Count - drug effects
- Random Allocation - drug effects
- Recurrence - drug effects
- Remission Induction - drug effects
- Thrombocytosis - blood
- Time Factors - blood